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Use of Antiepileptic Drugs and Lipid-Lowering Agents in The United States 
 
Scott Mintzer, MD, Vittorio Maio, PharmD, MSPH,  Kathleen Foley, PhD 
 
ABSTRACT 
 
Introduction  The extent to which enzyme-inducing antiepileptic drugs (EIAEDs) are used as first-
line treatment in the United States remains unknown. Studies suggest that EIAEDs produce elevation 
of serum lipids, which could require additional treatment. We assessed the current use of EIAED in 
monotherapy for epilepsy in the U.S., as well as the correlation between use of EIAEDs and subse-
quent new prescriptions for HMG-CoA reductase inhibitors (“statins”) for hyperlipidemia.  
 
Methods   We queried the MarketScan® databases between July 2009 to January 2013, covering 66 
million patients with commercial or supplemental Medicare insurance. We identified individuals who 
had a diagnosis of seizures, continuous enrollment in the database from 6 months prior to 24 months 
after the epilepsy diagnosis, no utilization of an AED or a statin prior to that diagnosis, and at least 1 
new AED prescription. We tabulated the fraction who were prescribed EIAEDs (phenytoin, car-
bamazepine, barbiturates) and those prescribed all other AEDs. Rates of new statin prescription be-
tween 1 and 24 months after AED prescription were assessed among the two groups, restricted to 
those with no prior history of vascular disease who had lipid serology obtained subsequent to the new 
AED prescription. 
 
Results   Of the 11,893 patients with newly-treated epilepsy, 2425 (20.4%) were started on an EIAED, 
and 9468 (79.6%) were started on a non-inducing AED. There was a consistent and significant trend 
for EIAEDs to be increasingly prescribed with increasing age (p<0.0001).  
Among patients meeting the criteria, a statin was newly prescribed in 66 of 496 (13.3%) EIAED-
treated patients, and in 178 of 1930 (9.2%)  non-inducing AED patients (p < 0.007). This difference 
remained significant after accounting for age and gender (p=0.015). A patient starting an EIAED was 
46% more likely to be subsequently prescribed a statin than a patient started on a non-inducing AED 
(95% CI 1.08 - 1.98). 
 
Conclusions   EIAED prescription for epilepsy appears to increase with increasing age in the U.S. de-
spite the absence of a cogent rationale for this practice, suggesting a failure to appreciate the complica-
tions of EIAED therapy among U.S. physicians. Statins were more often started in those newly-
prescribed EIAEDs than to those given non-inducing AEDs. These preliminary data provides further 
evidence suggesting that EIAEDs elevate lipids in a clinically meaningful manner.
  
1. INTRODUCTION 
 
Enzyme-inducing antiepileptic drugs (EIAEDs), including carbamazpine, phenytoin, and phe-
nobarbital, are among the most commonly-prescribed medications for seizures throughout the world. 
Mounting evidence indicates that these agents, probably via their widespread impact upon the cyto-
chrome P450 system, engender a host of metabolic derangements[1, 2], including elevations of serum 
lipids and other serologic markers of vascular risk[3]. These effects would be expected to materially 
increase the risk of vascular disease, based upon estimation from population studies in the cardiovas-
cular literature [4], and additional surrogate markers[5]. 
Ideally, a direct assessment could be made to determine whether exposure to these drugs is as-
sociated with elevated incidence of vascular events. But the hyperlipidemia caused by EIAEDs might 
easily and incidentally be picked up by primary care physicians performing routine health screening. If 
the lipid elevation is clinically significant, then treatment with an lipid-lowering agent may be initi-
ated, often with no knowledge that the anticonvulsant is contributing to the problem. This may add to 
the costs and potential complications of care for patients. 
Currently, there are little or no data to establish the extent to which EIAEDs are still being used 
as first-line therapy in the United States. Thus, the goals of this preliminary investigation were two-
fold: first, to assess patterns of new use of EIAEDs in the American epilepsy population; and second, 
to determine whether new AED therapy for probable epilepsy is associated with a higher incidence of 
subsequent initiation of treatment with an HMG-CoA-reductase inhibitor (“statin”). As our goal was to 
examine whether statins were needed for hyperlipidemia, we focused on the subset of patients who 
had a lipid panel drawn after AED initiation. 
 
 
 
2. METHODS 
 
Our data source for this investigation is the Truven Health MarketScan®  Research Databases 
(Truven Health, Ann Arbor, MI). In this investigation we utilized the Commercial and Medicare Data-
bases, which aggregate claims data from over 130 different carriers covering employees of more than 
100 medium- and large-sized companies. The Medicare database contains medical and prescription 
drug claims for patients with supplemental employer-sponsored Medicare insurance. The analysis used 
data from July 2009 to January 2013, encompassing 66 million unique individuals. All data are de-
identified and include age, gender, outpatient and inpatient diagnoses, tests and procedures ordered, 
and prescriptions. 
From this we included individuals of all ages meeting the following criteria: 1) continuous en-
rollment in the database for at least 6 months without a diagnosis of epilepsy or seizures (ICD-9 codes 
345.xx or 780.39), and not on any treatment with an AED; 2) a diagnosis of epilepsy or seizures, ap-
pearing on at least two occasions at least 1 day apart; 3) a new, filled prescription for an AED (pheno-
  
barbital, phenytoin, primidone, carbamazepine, valproate, gabapentin, lamotrigine, topiramate,  oxcar-
bazepine, levetiracetam, zonisamide, or pregabalin) for at least 30 days; 4) follow-up in the database 
for at least 24 months subsequent to this prescription. We divided this population into two groups: 
those started on phenytoin, carbamazepine, phenobarbital or primidone comprised the EIAED group, 
while those started on any of the other AEDs were considered the non-inducing AED group. Any pa-
tient starting medications in both classes simultaneously was excluded. 
After looking at patterns of AED prescription in this cohort, our next objective was to ascertain 
those who were prescribed statins for reduction of lipids. To do this, we limited the aforementioned 
cohort to those age 25 and older who were not taking a statin prior to AED initiation, had no prior 
codes for any vascular disease of the heart brain, or peripheral vessels (ICD-9 codes 410-414, 433-
438, 440, 443.9 and 444), and had had a lipid panel obtained subsequent to the AED prescription. This 
was done to maximize the likelihood that the statin was prescribed for hyperlipidemia rather than for 
another purpose. We examined the incidence of new statin prescriptions in this subgroup beginning 30 
days after AED prescription, comparing those prescribed EIAEDs and those prescribed non-inducing 
AEDs. 
Outcomes were calculated in a binary fashion for each patient over the whole 24 month follow-
up period (i.e. new vascular diagnosis or not, new statin prescription or not). Chi-squared tests for ind-
pendence and trend were used to examine patterns of AED prescription by age and gender. A logistic 
regression model was utilized to examine whether statin use differed by type of AED prescribed with 
gender and age as covariates and p<0.05 used as the marker for significance. Limitations of use of the 
dataset precluded more extensive analysis of potential confounders. Data were analyzed using SAS 
(SAS Institute, Cary, NC). 
 
 
3. RESULTS 
 
3.1 Overall use of inducing and non-inducing AEDs 
 
Over the study period, there were a total of 11,893 patients who met the inclusion criteria. Of 
these, 2425 (20.4%) were started on an EIAED, and 9468 (79.6%) were started on a non-inducing 
AED. Demographic data for the population are presented in the Table. The group prescribed EIAEDs 
was significantly older (49 vs. 38, p<0.0001). In fact, when patients were divided into age groups, 
there was a very significant trend to prescribe EIAEDs at a higher rate with increasing age (Chi-
squared for trend, p<0.0001). Male patients were significantly more likely to be started on an EIAED 
than female patients (22.6% vs. 18.5%, p<0.0001). Variation in the use of EIAEDs among different 
geographic regions and different types of health plans is also seen in the Table. 
 
3.2 Statin use in AED-treated patients 
 
  
The analysis of subsequent statin use is shown in the Figure. Among all 11,893 patients, 7770 
(65.3%) were age 25 years or older, and 4898 of those (63%) had no prior history of statin use or vas-
cular diagnoses. A lipid panel was subsequently obtained in about half of these 4898 patients: 49.2% 
of those started on non-inducing AEDs, and 50.8% of those taking EIAEDs (p>0.10). Among those in 
whom lipids were checked, 178 of the 1930 non-inducing AED patients (9.2%) were subsequently 
prescribed a statin, while 66 of the 496 EIAED-treated patients (13.3%) were subsequently prescribed 
a statin. The difference in incident statin prescription was highly significant between the two groups 
(p=0.007), and remained significant even after accounting for age and gender (p=0.015). Patients 
started on an EIAED were 46% more likely to be subsequently treated with a statin than those started 
on a non-inducing AEDs (95% CI  1.08 - 1.98). 
 
 
4. DISCUSSION 
 
Some noteworthy findings emerged from this investigation. First, we found that patients re-
ceiving a new AED in monotherapy were significantly more likely to be treated with an EIAED with 
increasing age in the United States. While it is known that elderly often receive EIAEDs, our finding 
was not restricted to the elderly population, showing instead a clear and consistent trend beginning 
with children and continuing through adults of all ages. To our knowledge, this has not been reported 
before, and certainly not in the American population. 
This finding is unexpected, and somewhat difficult to explain. Concerns about the effects of 
EIAEDs on bone health have existed for over four decades, and more recent evidence has also sug-
gested potential deleterious effects of these drugs on cholesterol and other cardiovascular markers[2, 3, 
11]; these are conditions for which advancing age is a considerable risk factor. Furthermore, the pro-
pensity of EIAEDs to cause drug interactions has likewise been widely known for decades, and the use 
of co-medications also increases substantially with age in the epilepsy population, as in all popula-
tions[6, 12]. There are also formal head-to-head studies indicating that non-inducing agents are equally 
effective, if not superior to, EIAEDs in the elderly, while avoiding drug interactions and other meta-
bolic difficulties[7, 8]. Thus, we can find no cogent explanation for this finding, which is contrary to 
expert opinion[9]. Further study is clearly necessary to determine whether this finding is valid, and if 
so, what might be driving this behavior. 
We also found that females were less likely to receive EIAEDs than males. Perhaps this is due 
to the cosmetic side effects of phenytoin, or it might reflect avoidance of the interaction between EI-
AEDs and oral contraceptives[10]. Variation in EIAED usage by geographic region is complex and 
may require in-depth analysis of physician and patient behavior to be properly understood. There was 
little apparent variation in EIAED use among different types of commercial insurance except for a sig-
nificantly higher rate of EIAED use amongst those enrolled in Comprehensive plans; the reasons for 
this are not apparent and also merit further exploration. 
Another important finding from our study is that once patients receive new AED therapy for 
seizures, those prescribed EIAEDs are almost 50% more likely to be subsequently started on lipid-
  
lowering therapy than those who receive non-inducing AEDs. This finding persisted even after ad-
justment for age, and so cannot be attributed the EIAED group being older. While statins are com-
monly used for secondary prevention of cardiovascular disease and stroke even in the setting of nor-
mal cholesterol, we excluded any patient with a history of such disease from this portion of the analy-
sis, so it is unlikely that many statin prescriptions in this cohort were for this purpose. Furthermore, a 
very similar fraction of patients had lipids checked in the inducing and non-inducing AED groups, so 
there was no evidence of ascertainment bias (e.g. more frequent lipid screening in those getting EI-
AEDs). Thus, the most likely explanation for this finding is that EIAEDs increase serum lipids to a 
degree that is judged clinically meaningful by practitioners, and thus worthy of treatment, in a statisti-
cally significant fraction of patients. 
Note should be made that the fraction of patients requiring a statin after epilepsy treatment is 
substantial, constituting 5% of the whole group and 10% of those in whom lipid serology was ob-
tained; as lipids were only checked in 50% of patients, that 5% number could easily be much higher.  
Thus, our data would suggest that treating all epilepsy patients with EIAEDs results in 3 - 4% of the 
cohort requiring a statin prescription which would not have be needed had a non-inducing AED been 
used. The true impact of EIAEDs in this regard is likely much greater than this, of course, since we 
excluded all those who had a history of prior statin treatment; many of this latter group of patients may 
require either higher doses or the addition of another lipid-lowering agent because of both the native 
lipid-elevating effects of EIAEDs and the induction of metabolism of most statin drugs by EI-
AEDs[12]. This suggests that the use of EIAEDs may constitute not just an important health issue, but 
also an economic one. 
The statin findings reinforce the difficulties inherent in assessing the potential atherogenic 
properties of EIAEDs. We looked preliminarily in this patient group, and after accounting for age did 
not find the incidence of vascular disease to be significantly higher among EIAED-treated patients 
(data not shown). However, our inability to account for differential prescription for statins, as well as a 
host of other covariates that are pertinent to vascular disease risk (e.g. use of antiplatelet agents, hyper-
tension, diabetes), make this comparison of dubious utility. A fully-adjusted epidemiologic study, with 
a longer time horizon than the 24 months available to us in the present study, is greatly needed to ad-
dress this crucial issue more definitively. 
The present study has several important limitations. As mentioned previously, this was a pre-
liminary analysis in which we were unable to account for co-variates other than age and gender. Ad-
justment for covariates may be relevant not just to statin use, but also to the choice of AED. The lack 
of covariates precluded us doing an appropriate examination of other factors such as subsequent dis-
ease incidence or hospital admission rates. We were also limited to a 2-year forward-looking time ho-
rizon and a 6-month backward-looking period during which there was no epilepsy diagnosis because 
of the dataset; ideally such a study should be able to exclude the diagnosis of epilepsy and the use of 
AEDs or statins for at least a year prior to the index date, but doing so would have abridged the time 
horizon even more. The findings here are limited to the population with commercial or supplemental 
Medicare insurance, and thus their generalizability to other segments of the U.S. population (e.g. those 
of lower economic status with Medicaid insurance) is uncertain. Another issue is that claims databases 
  
do not have some pieces of data that may be relevant to prescribing choices (e.g. race, obesity, smok-
ing), nor were the actual results of lipid panels available for review to document their elevation. Thus, 
while we may make a reasonably strong inference that most of the statin prescriptions were for hyper-
cholesterolemia, we can be be certain of this. Finally, the choice of whether to take a drug, and what 
drug is chosen, depend upon many aspects of both patient and physician behavior that cannot be as-
sessed in a study of this nature. Thus, the use of prescription choice as an outcome measure should al-
ways be interpreted cautiously, and whenever possible should be bolstered by objective criteria that do 
not depend upon the subjective choices of practitioners and patients. In this case, abundant serologic 
data attest to the lipid-elevating effects of EIAEDs[3], so that interpretation of the findings may be 
considered with this in mind. 
Thus, caveats notwithstanding, we believe these data support the findings of serologic studies 
in implicating EIAEDs as a cause of significant hypercholesterolemia. Our data also suggest that a 
substantial education gap exists in U.S. physicians’ knowledge of the dangers of EIAEDs. Programs to 
address this gap may be important to promote the second half of the oft-stated epilepsy treatment goal 
of “no seizures, no side effects.” 
 
  
TABLE. Use of enzyme-inducing antiepileptic drugs (EAIEDs) in various subsets of the American 
commerically-insured population. 
AGE GROUP COUNT % OF CO-HORT 
# ON EI-
AEDs % ON EIAEDs # on non-inducers 
% on non-
inducers 
0-17 2936 24.7% 259 8.8% 2677 91.2% 
18-34 2106 17.7% 340 16.1% 1766 83.9% 
35-44 1320 11.1% 294 22.3% 1026 77.7% 
45-54 1801 15.1% 476 26.4% 1325 73.6% 
55-64 1779 15.0% 495 27.8% 1284 72.2% 
65+ 1951 16.4% 561 28.8% 1390 71.2% 
    p<0.0001   
GENDER       
Male 5453 45.9% 1235 22.6% 4218 77.4% 
Female 6440 54.2% 1190 18.5% 5250 71.5% 
    p<0.0001   
CENSUS DIVISION       
New England 534 4.5% 102 19.1% 432 70.9% 
Middle Atlantic 1665 14.0% 342 20.5% 1323 79.5% 
East North Central 2591 21.8% 549 21.2% 2042 78.8% 
West North Central 542 4.6% 104 19.2% 438 70.8% 
South Atlantic 2208 18.6% 398 18.0% 1810 72.0% 
East South Central 926 7.8% 172 18.6% 754 71.4% 
West South Central 1053 8.9% 239 22.7% 814 77.3% 
Mountain 646 5.4% 137 21.2% 509 78.8% 
Pacific 1683 14.2% 370 22.0% 1313 78.0% 
Missing 45 0.4% 12 26.7% 33 73.3% 
       
PLAN TYPE       
Comprehensive 1467 12.3% 418 28.5% 1049 71.5% 
Exclusive Provider 
Organization 149 1.3% 29 19.5% 120 80.5% 
Health Maintenance 
Organization 1999 16.8% 386 19.3% 1613 80.7% 
Point-Of-Service 1006 8.1% 199 19.8% 807 80.2% 
Preferred Provider 
Organization 5580 46.9% 1067 19.1% 4513 80.9% 
Consumer-Driven 
Health Plan 539 4.5% 106 19.7% 433 80.3% 
High-Deductible 
Health Plan 211 1.8% 32 15.2% 179 84.8% 
Unknown 942 7.9% 188 20.0% 754 80.0% 
Total Patients 11893 100.0% 2425 20.4% 9468 79.6% 
  
 
FIGURE. Flow chart for analysis of subsequent statin prescription among patients with newly-
treated epilepsy, divided by type of antiepileptic used for treatment. 
 
CVD = cardiovascular disease (including stroke and peripheral vascular disease); EIAED = enzyme-inducing antiepileptic 
drug 
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